Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
Open accessThe DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index.
Abstract
Chemoresistance is a major problem in the therapeutic management of pancreatic cancer, concurring to poor clinical outcome. A number of mechanisms have been proposed to explain resistance to gemcitabine, a standard of care for this malignancy, among which is included aberrant miRNA expression. In the current study, we investigated the role of miR-217, which is strongly down-regulated in cancerous, compared to normal, pancreatic tissues or cells, in sensitizing human pancreatic cancer cell lines to this drug. The low expression of miR-217 in pancreatic cancer patients was confirmed in two gene expression datasets (GSE41372 and GSE60980), and the prognostic value of two target genes (ANLN and TRPS1), was estimated on clinical data from the Tumor Cancer Genome Atlas (TCGA). Transfecting miR-217 mimic in pancreatic cancer cells reduced viability, enhanced apoptosis, and affected cell cycle by promoting a S phase arrest in gemcitabine-treated cells. Moreover, in drug-exposed cells subjected to miR-217 forced expression, a down-regulation for several genes involved in cancer drug resistance was observed, many of which are cell cycle regulators, such as CCND1, CCNE1, CDK2, CDKN1A, CDKN1B, while others, such as ARNT, BRCA1, BRCA2, ELK1, EGFR, ERBB4, and RARA are involved in proliferation and cell cycle progression. Our results support the notion that miR-217 enhances pancreatic cancer sensitivity to gemcitabine, mainly impairing cell cycle progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with previous reports, GEM induced an S‐phase arrest in both cell lines as well as a G1 arrest in PANC‐1 cells [22, 23] and this was accompanied by increased cyclin A and cyclin B1 levels.”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Xiao, Y., Deng, T., Su, C., & Shang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.6076 · Cited by 49 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundRetractedYin, Z., & Ren, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s176618 · Cited by 17 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundRetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“The seventh most common cause of death for cancer worldwide and third in developed countries, pancreatic ductal adenocarcinoma (PDAC) is usually a fatal disease [1], with a 5 year survival rate of around 9% from the time of diagnosis [2].”
BackgroundSwitching from Repression to Activation: MicroRNAs Can Up-Regulate Translation
Vasudevan, S., Tong, Y., & Steitz, J. A. (2007) · Science · doi:10.1126/science.1149460 · Cited by 2,822
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269 · cited 1×
“The seventh most common cause of death for cancer worldwide and third in developed countries, pancreatic ductal adenocarcinoma (PDAC) is usually a fatal disease [1], with a 5 year survival rate of around 9% from the time of diagnosis [2].”
BackgroundEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584 · cited 1×
“By modulating gene expression, miRNAs influence several biological processes, among which are development, differentiation, proliferation, and apoptosis [17]; when their expression is dysregulated, alterations of such processes may trigger carcinogenesis [18].”
BackgroundMicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
MicroRNA-373 induces expression of genes with complementary promoter sequences
Place, R. F., Li, L.-C., Pookot, D., Noonan, E. J., & Dahiya, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707594105 · Cited by 1,230
Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR
Lytle, J. R., Yario, T. A., & Steitz, J. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703820104 · Cited by 1,196
Cited by
Xia, W., Chen, W., Ni, C., Meng, X., Wu, J., Yang, Q., Tang, H., Yuan, H., & Shan, F. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01672-x · Cited by 52
Bravo-Vázquez, L. A., Frías-Reid, N., Ramos-Delgado, A. G., Osorio-Pérez, S. M., Zlotnik-Chávez, H. R., Pathak, S., Banerjee, A., Bandyopadhyay, A., Duttaroy, A., & Paul, S. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101579 · Cited by 31
“miR-217 Downregulated – Induced miR-217 expression enhances gemcitabine sensitivity [132]”
BackgroundMicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2
Dutta, M., Das, B., Mohapatra, D., Behera, P., Senapati, S., & Roychowdhury, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120592 · Cited by 27
Yang, L., Gong, X., Wang, J., Fan, Q., Yuan, J., Yang, X., Sun, X., Li, Y., & Wang, Y. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154022 · Cited by 27
Wu, R., Su, Z., Le, Z., Pei, R., Ding, Y., Li, D., Zhu, S., Xu, L., Zhao, W., & Zhou, W. (2023) · Stem Cells International · doi:10.1155/2023/6510571 · Cited by 18
Metadata
- Authors
- Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Binda, Elena
- Pazienza, Valerio
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-04-26
- Volume
- 11
- Issue
- 5
- Pages
- 639
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8146031
- OpenAlex
- W3158790987
- Cited by
- 26
- References
- 61
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute (Ricerca Corrente 2018-2020)
- Associazione Italiana per la Ricerca sul Cancro (IG2019-ID23006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- miR-217, gemcitabine, pancreatic cancer, chemoresistance, microRNA restoration, cell cycle arrest, S phase arrest, apoptosis, anillin, TRPS1, cell cycle regulators, drug sensitivity
- MeSH terms
- Gemcitabine, Cell Survival, Deoxycytidine, Humans, Pancreatic Neoplasms, Prognosis, Apoptosis, Cell Cycle Proteins, Drug Resistance, Neoplasm, Databases, Genetic, MicroRNAs, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. https://app.cochat.ai/papers/10.3390/biom11050639
- The paper
- Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V. (2021). Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels. Biomolecules. https://doi.org/10.3390/biom11050639
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.